Goldschmidt Marc; Frishman, William H.American Journal of Therapeutics: April 1995 Original Articles: PDF Only Buy Abstract Ranolazine is a new, orally active pharmacologic agent that experimentally has been shown to favorably affect myocardial metabolism during myocardial ischemia. It has no direct action on myocardial hemodynamics but appears to improve ventricular functioning by blocking uptake of free fatty acids by the heart while shifting metabolism to anaerobic glycolysis during myocardial ischemia. Preliminary clinical studies suggest a dose-dependent antianginal, and anti-ischemic effect and an excellent safety profile for this unique drug. However, the results of a recent double-blind efficacy and safety study showed no antianginal effect of ranolazine (30–120 mg thrice daily) when compared to placebo. © Williams & Wilkins 1995. All Rights Reserved.